PharmAust Ltd - PAA share price
About PharmAust Ltd
PharmAust Limited is an Australian clinical-stage biotechnology company that focuses on developing therapeutics for various conditions, including cancer, neurodegenerative diseases, viral infections in humans, and cancer in animals. Their lead candidate, Monepantel (MPL), is an inhibitor of the mTOR pathway, a pathway with significant implications for cancer growth and neurodegenerative diseases. MPL has undergone Phase I clinical trials in humans and Phase II clinical trials in dogs. Additionally, the company has initiated a preclinical program to evaluate the anticancer properties of its portfolio of aminoacetonitrile (AAD) compounds. PharmAust Limited's wholly-owned subsidiary, Epichem Pty Ltd, is also involved in advancing waste conversion and re-purposing technology known as Oxidative Hydrothermal Dissolution (OHD).
Company Profile
Disclaimer: The above financial data is sourced from EODHD and is for informational purposes only. Veye does not guarantee the accuracy or completeness of this data. Investors should conduct their own research and consult with a financial advisor before making investment decisions.
Price Summary
Try Veye Free for 7 Days
Expert ASX stock picks, in-depth research & buy/sell signals — free for a full week.
No credit card required
Price Chart (PAA)
TOP ASX STOCKS Worth Watching
- ✓ Instant Access
- ✓ No Credit Card Required
- ✓ Free to join · No spam
Free to join · No spam · Unsubscribe anytime
By providing your details, you agree to Veye's Terms & Conditions, Privacy Policy, and Financial Services Guide and to receive marketing offers. Before you access our services, please read the Financial Services Guide available here.
Discover the Top ASX Stocks to Invest in 2026!
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Reports from Veye
Latest Article
